Moleculin Biotech, Inc.
MBRXNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$25.1M | −$26.6M | −$29.6M | −$30.6M | −$23.0M | −$19.7M |
| Net income | −$33.6M | −$26.0M | −$29.8M | −$29.0M | −$15.9M | −$17.4M |
| Total assets | $22.1M | $16.9M | $38.2M | $57.4M | $84.1M | $29.0M |
| Total liabilities | $7.1M | $5.7M | $12.1M | $5.2M | $5.1M | $11.3M |
| Equity | $15.0M | $11.2M | $30.9M | $52.2M | $79.0M | $17.8M |
| EPS (diluted) | $-28.42 | $-189.14 | $-15.07 | $-15.22 | $-0.59 | — |
| Shares out. | 14.0M | 2.2M | 28.6M | 28.6M | 28.4M | 53.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −223.6%
- Return on assets
- −151.7%
- Return on capital (ROCE)
- −164.4%
- Liabilities / assets
- 32.2%
- Debt / equity
- 0.47×
- Book value / share
- $1.07
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -34.92distress
- Accruals / assets
- −48.9%clean
- Piotroski F-Score
- 4/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 14, 2019
- NT 10-Kmissed a reporting deadline ↗Apr 3, 2017
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2016
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Picker Donald HOfficer — Chief Science Officer | Nov 4, 2025 | Option exercise | 8,750 | — |
| Klemp Walter VOfficer — CEO and President | Nov 4, 2025 | Option exercise | 28,750 | — |
| Foster Jonathan P.Officer — Chief Financial Officer | Nov 4, 2025 | Option exercise | 20,625 | — |
| Foster Jonathan P.Officer — Chief Financial Officer | Jun 20, 2025 | Option exercise | 2,711 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 527,786 | 2.1 | +57.9% |
| Apr 30, 2026 | 334,361 | 2.6 | +141.0% |
| Apr 15, 2026 | 138,763 | 1.7 | +21.8% |
| Mar 31, 2026 | 113,910 | 1.1 | +4.0% |
| Mar 13, 2026 | 109,555 | 1.0 | -42.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureMay 29, 2026
- Regulation FD disclosureMay 26, 2026
- Regulation FD disclosureMay 22, 2026
- Results of operationsMay 15, 2026
- Regulation FD disclosureMay 13, 2026
- Regulation FD disclosureMay 12, 2026
- Regulation FD disclosureMay 8, 2026
- Regulation FD disclosureApr 23, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KFORM 8-KMay 29, 2026
- 8-KFORM 8-KMay 26, 2026
- 8-KFORM 8-KMay 22, 2026
- 8-KFORM 8-KMay 15, 2026
- 10-QFORM 10-QMay 14, 2026
- 8-KFORM 8-KMay 13, 2026
- 8-KFORM 8-KMay 12, 2026
- 8-KFORM 8-KMay 8, 2026
- 8-KFORM 8-KApr 23, 2026
- 8-KFORM 8-KApr 15, 2026
- EFFECTApr 14, 2026
- 10-K/AFORM 10-K/AApr 14, 2026
- 424B3FORM 424B3Apr 14, 2026
- CORRESPApr 10, 2026
- UPLOADApr 2, 2026